(Q37411669)

English

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

scientific article published on 13 October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. (English)

1 reference

Europe PubMed Central

20 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

Petra Muus

1 reference

Europe PubMed Central

20 August 2017

3

object named as

Stefan Suciu

1 reference

Europe PubMed Central

20 August 2017

author name string

Franco Mandelli

1

1 reference

Europe PubMed Central

20 August 2017

Marco Vignetti

2

1 reference

Europe PubMed Central

20 August 2017

Roberto Stasi

4

1 reference

Europe PubMed Central

20 August 2017

Maria-Concetta Petti

5

1 reference

Europe PubMed Central

20 August 2017

Giovanna Meloni

6

1 reference

Europe PubMed Central

20 August 2017

Filippo Marmont

8

1 reference

Europe PubMed Central

20 August 2017

Jean-Pierre Marie

9

1 reference

Europe PubMed Central

20 August 2017

Boris Labar

10

1 reference

Europe PubMed Central

20 August 2017

Xavier Thomas

11

1 reference

Europe PubMed Central

20 August 2017

Francesco Di Raimondo

12

1 reference

Europe PubMed Central

20 August 2017

Roel Willemze

13

1 reference

Europe PubMed Central

20 August 2017

Vincenzo Liso

14

1 reference

Europe PubMed Central

20 August 2017

Felicetto Ferrara

15

1 reference

Europe PubMed Central

20 August 2017

Liliana Baila

16

1 reference

Europe PubMed Central

20 August 2017

Paola Fazi

17

1 reference

Europe PubMed Central

20 August 2017

Robert Zittoun

18

1 reference

Europe PubMed Central

20 August 2017

Sergio Amadori

19

1 reference

Europe PubMed Central

20 August 2017

Theo de Witte

20

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

13 October 2009

1 reference

Europe PubMed Central

20 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

20 August 2017

27

1 reference

Europe PubMed Central

20 August 2017

5397-5403

1 reference

Europe PubMed Central

20 August 2017

32

1 reference

Europe PubMed Central

20 August 2017

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

A systematic overview of chemotherapy effects in acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

Acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

6 September 2017

Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

26 June 2018

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

2 September 2018

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773224

2 September 2018

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.20.6490

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37411669&oldid=2130983578"